KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB:GCAN) a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, today announced that the Company’s subsidiary has entered into a comprehensive manufacturing agreement with Bio Products Laboratory ("BPL") to produce the Company’s lead drug candidate, VitiGam™, from plasma derived from Vitiligo donors. BPL is a division of National Health Service Blood and Transplant, a unit of the United Kingdom National Health Service. BPL is a leading manufacturer of plasma-based products distributed worldwide.
